Librela (20 - 30 kg)
Active substance
ATC code
Species
Dogs.
Indications
For the alleviation of pain associated with osteoarthritis in dogs.
Dose to be administered and administration route
Subcutaneous use.
Dosage and treatment schedule:
The recommended dose is 0.5-1.0 mg/kg bodyweight, once a month
Dogs weighing <5.0 kg:
Aseptically withdraw 0.1 ml/kg from a single 5 mg/ml vial and administer subcutaneously.
For dogs between 5 and 60 kg administer the entire content of the vial (1 ml) according to the table below:
|
LIBRELA strength (mg) to be administered |
|||||
|
Bodyweight (kg) of dog |
5 |
10 |
15 |
20 |
30 |
|
5.0-10.0 |
1 vial |
||||
|
10.1-20.0 |
1 vial |
||||
|
20.1-30.0 |
1 vial |
||||
|
30.1-40.0 |
1 vial |
||||
|
40.1-60.0 |
1 vial |
||||
|
60.1-80.0 |
2 vials |
||||
|
80.1-100.0 |
1 vial |
1 vial |
|||
|
100.1-120.00 |
2 vials |
||||
For dogs above 60 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the content from each required vial into the same syringe and administer as a single subcutaneous injection (2 ml).
Adverse reactions
Dogs:
|
Uncommon (1 to 10 animals / 1,000 animals treated): |
Injection site reaction (e.g. injection site swelling, injection site warmth)1. |
|
Rare (1 to 10 animals / 10,000 animals treated): |
Polydipsia. Polyuria. |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Hypersensitivity reaction (anaphylaxis, facial swelling, pruritus)2, immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia. |
1 Mild
2 In case of such reactions, appropriate symptomatic treatment should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section 16 of the package leaflet for respective contact details.
